IP Library Granted Patent US 12,605,520
Granted Patent B2
US 12,605,520 · App. 18/184,847 · Granted Apr 21, 2026

Delivery of ultra pure nitric oxide (NO)

Inventors: David H. Fine (Cocoa Beach, FL); Gregory Vasquez (Cocoa, FL); Bryan Johnson (Orlando, FL); Ryan Denton (Central City, CO); Lucas G. Gamero (Oviedo, FL)
Assignee: VERO Biotech Inc.
A61M16/122A61M16/10A61M16/12C01B21/24A61M2016/0027A61M16/0666A61M2016/102A61M16/105A61M16/1055A61M16/107A61M16/1075A61M2202/0266A61M2202/0275A61M2202/03A61M2205/0238A61M2205/18A61M2205/3368A61M2205/3653A61M2205/7518A61M2205/8206A61M2207/10A61M2209/088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,605,520
App. No.
18/184,847
Granted
Apr 21, 2026
Kind
B2
Abstract

A system for delivering a therapeutic amount of nitric oxide can include a reservoir including a restrictor with a length of at least 0.5 inches and at most 2 inches covered by a metal sheath, a gas supply, and a delivery conduit. A delivery conduit can include at least one cartridge and a patient interface. The at least one cartridge can include a surface-active material and a reducing agent.

Claims (20)

1 . A disposable module comprising:

a restrictor connected to a reservoir comprising a source of nitrogen dioxide gas, wherein the restrictor has a dimension defined by a total pressure drop effective to provide a predetermined amount of nitrogen dioxide gas; and wherein the restrictor and the reservoir are configured to be heated to a temperature of at most 200° C., and

at least one cartridge configured to receive the predetermined amount of nitrogen dioxide gas through the restrictor and to form a therapeutic amount of nitric oxide.

2 . The disposable module of claim 1 , wherein the restrictor is a capillary tube.

3 . The disposable module of claim 1 , wherein the restrictor is coupled to the at least one cartridge through a delivery conduit.

4 . The disposable module of claim 3 , wherein the predetermined amount of nitrogen dioxide received by the at least one cartridge is mixed with a gas.

5 . The disposable module of claim 4 , wherein the gas is delivered from a gas supply.

6 . The disposable module of claim 5 , wherein the gas supply is coupled to the delivery conduit.

7 . The disposable module of claim 1 , wherein the at least one cartridge comprises a surface-active material and a reducing agent.

8 . A system comprising a disposable module of claim 1 and a base unit.

9 . The system of claim 8 , wherein the base unit comprises a gas supply.

10 . The system of claim 8 , wherein the base unit comprises one or more of batteries, sensors and/or alarm electronics.

11 . The system of claim 8 , wherein the system is portable.

12 . A method, comprising:

heating to a temperature of at most 200° C. a reservoir comprising a source of nitrogen dioxide to form the nitrogen dioxide;

passing a predetermined amount of nitrogen dioxide through a restrictor to at least one cartridge, wherein the predetermined amount of nitrogen dioxide is defined by the restrictor's dimension; and

forming a therapeutic amount of nitrogen oxide in the at least one cartridge.

13 . The method of claim 12 , forming a gas mixture by mixing the predetermined amount of nitrogen dioxide with a gas from a gas supply in a delivery conduit prior to entering the at least one cartridge.

14 . The method of claim 13 , wherein the therapeutic amount of nitric oxide is formed by flowing the gas mixture through at least one cartridge, wherein the at least one cartridge comprises a surface-activated material and a reducing agent.

15 . The method of claim 14 , delivering the therapeutic amount of nitrogen oxide to a patient.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2023
From: FINE, DAVID H.; VASQUEZ, GREGORY; JOHNSON, BRYAN; DENTON, RYAN; GAMERO, LUCAS G.
To: GENO LLC
Reel/Frame 064015/0493 →
CHANGE OF NAME Recorded Jun 21, 2023
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 064050/0076 →
CHANGE OF NAME Recorded Jun 21, 2023
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 064050/0079 →
Continuity (5)
Continuation 16247516 · Jan 14, 2019
Continuation 14546373 · Nov 18, 2014
Continuation 13094535 · Apr 26, 2011
Provisional Application 61328010 · Apr 26, 2010
Related Publication 20230398323A1 · Dec 14, 2023
References Cited (66)
US 2799159A · Sabol · 1957 [cited by applicant]
US 3393047A · Steinmetz-Schmaltz · 1968 [cited by applicant]
US 3856204A · Chand · 1974 [cited by applicant]
US 3903883A · Pecina et al. · 1975 [cited by applicant]
US 4399942A · Chand · 1983 [cited by applicant]
US 4621632A · Bartels et al. · 1986 [cited by applicant]
US 4676237A · Wood et al. · 1987 [cited by applicant]
US 4717675A · Sievers · 1988 [cited by applicant]
US 4993436A · Bloom, Jr. · 1991 [cited by applicant]
US 5062145A · Zwaan et al. · 1991 [cited by applicant]
US 5108705A · Rounbehler et al. · 1992 [cited by applicant]
US 5156334A · Kimbell et al. · 1992 [cited by applicant]
US 5264198A · Grzyll · 1993 [cited by applicant]
US 5336156A · Miller et al. · 1994 [cited by applicant]
US 5365776A · Lehmann · 1994 [cited by applicant]
US 5437410A · Babasade · 1995 [cited by applicant]
US 5639441A · Sievers et al. · 1997 [cited by applicant]
US 5692495A · Sheu · 1997 [cited by examiner]
US 5938985A · Rodgers · 1999 [cited by applicant]
US 6083399A · Jameson et al. · 2000 [cited by applicant]
US 6095134A · Sievers et al. · 2000 [cited by applicant]
US 6368870B1 · Harp · 2002 [cited by applicant]
US 6581599B1 · Stenzler · 2003 [cited by applicant]
US 6749834B2 · Fein et al. · 2004 [cited by applicant]
US 6843388B1 · Hollars · 2005 [cited by applicant]
US 7040313B2 · Fine · 2006 [cited by applicant]
US 7165546B2 · Frankie et al. · 2007 [cited by applicant]
US 7355216B2 · Yang et al. · 2008 [cited by applicant]
US 7560076B2 · Rounbehler et al. · 2009 [cited by applicant]
US 7618594B2 · Rounbehler et al. · 2009 [cited by applicant]
US 8057742B2 · Rounbehler et al. · 2011 [cited by applicant]
US 8066904B2 · Fine · 2011 [cited by applicant]
US 8079998B2 · Hole et al. · 2011 [cited by applicant]
US 8083997B2 · Rounbehler et al. · 2011 [cited by applicant]
US 8226916B2 · Rounbehler et al. · 2012 [cited by applicant]
US 8256430B2 · Torchia et al. · 2012 [cited by applicant]
US 8371296B2 · Fine · 2013 [cited by applicant]
US 8609028B2 · Rounbehler et al. · 2013 [cited by applicant]
US 8887720B2 · Fine · 2014 [cited by applicant]
US 10179222B2 · Fine · 2019 [cited by applicant]
US 11000484B2 · Fine · 2021 [cited by applicant]
US 20030062043A1 · Fine · 2003 [cited by examiner]
US 20060048779A1 · Rounbehler · 2006 [cited by examiner]
US 20060096596A1 · Occhialini et al. · 2006 [cited by applicant]
US 20060180147A1 · Rounbehler et al. · 2006 [cited by applicant]
US 20080257915A1 · Wold · 2008 [cited by applicant]
US 20080317874A1 · Fine et al. · 2008 [cited by applicant]
US 20090263578A1 · Lindfors et al. · 2009 [cited by applicant]
US 20090285731A1 · Rounbehler et al. · 2009 [cited by applicant]
US 20100003349A1 · Miller · 2010 [cited by applicant]
US 20100043788A1 · Fine et al. · 2010 [cited by applicant]
US 20120125328A1 · Rounbehler et al. · 2012 [cited by applicant]
WO 9210228A · 1992 [cited by applicant]
WO 9317741A1 · 1993 [cited by applicant]
WO 2008118360A1 · 2008 [cited by applicant]
WO 2010021941A1 · 2010 [cited by applicant]
WO 2010033916A1 · 2010 [cited by applicant]
WO 2011063335A1 · 2011 [cited by applicant]
WO 2011137124A1 · 2011 [cited by applicant]
Examination Report No. 1 for Australian Application No. 2011245476, dated Jul. 29, 2014, 3 pages. [cited by applicant]
Extended European Search Report for European Application No. 11775504.1, mailed Jul. 3, 2015, 6 pages. [cited by applicant]
Extended European Search Report for European Application No. 20177876.8, mailed on Jan. 15, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2011/033969 mailed Jul. 8, 2011, 9 pages. [cited by applicant]
Notice of Reasons for Refusal for Japanese Application No. 2013-508163, dated Dec. 19, 2014, 8 pages. [cited by applicant]
Notice of Reasons for Refusal for Japanese Application No. 2013-508163, dated Jul. 27, 2015, 8 pages. [cited by applicant]
Office Action for European Application No. 11775504.1, mailed Mar. 13, 2018, 5 pages. [cited by applicant]